Published • loading... • Updated
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
Summary by WBOC 16
2 Articles
2 Articles
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
